JPRN-jRCT2080222239未知3 期
DS-7113b phase III study A DS-7113b immediate release (IR) tablet long-term study in patients with cancer pain
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2013年9月30日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Cancer pain patients meeting any of followings
- •-Patients on opioid analgesics (oral morphine, oral oxycodone, transdermal fentanyl, or tramadol) less than 240 mg in morphine equivalent and judged effective to be treated with strong opioid analgesics
- •-Patients who have not been on opioid analgesics, whose VAS is 35 mm and over and judged necessary to be treated with strong opioid analgesics
- •-Patients who prefer to take DS-7113b IR tabletsafter completion of the study treatment of DS7113-A-J301 trial
排除标准
- •Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert of oxycodone hydrochloride and morphine hydrochloride, etc.
研究者
相似试验
未知
2 期
DS-7113b phase II studyModerate to severe cancer painJPRN-jRCT2080222120DAIICHISANKYO Co.,Ltd.
未知
2 期
DS-7113b injection phase II/III study (intravenous administration)Moderate to severe cancer painJPRN-jRCT2080222684DAIICHISANKYO Co.,Ltd.
未知
2 期
DS-7113b injection phase II/III study (subcutaneous injection)JPRN-jRCT2080222685DAIICHISANKYO Co.,Ltd.
未知
1 期
Phase I study of DS-7113bHealthy volunteersJPRN-jRCT2080222121DAIICHISANKYO Co.,Ltd.30
未知
3 期
DS-7113b phase III studyModerate to severe cancer painJPRN-jRCT2080222289DAIICHISANKYO Co.,Ltd.